Recent outbreaks of hantavirus, including Andes virus cases in 2026, have intensified research interest, yet all leading candidates remain in early preclinical stages with mRNA, DNA, and subunit platforms still undergoing animal testing and immunogenicity studies. Standard regulatory pathways for novel vaccines require sequential Phase 1–3 human trials plus manufacturing scale-up, timelines that typically span several years even under accelerated conditions, with no candidates currently positioned for 2026 approval or licensure outside limited existing options like South Korea’s Hantavax. Trader consensus at 93.5% “No” reflects these extended development hurdles and the absence of emergency authorization pathways comparable to Operation Warp Speed.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$117,642 Vol.
$117,642 Vol.
Dec 31, 2026
$117,642 Vol.
$117,642 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent outbreaks of hantavirus, including Andes virus cases in 2026, have intensified research interest, yet all leading candidates remain in early preclinical stages with mRNA, DNA, and subunit platforms still undergoing animal testing and immunogenicity studies. Standard regulatory pathways for novel vaccines require sequential Phase 1–3 human trials plus manufacturing scale-up, timelines that typically span several years even under accelerated conditions, with no candidates currently positioned for 2026 approval or licensure outside limited existing options like South Korea’s Hantavax. Trader consensus at 93.5% “No” reflects these extended development hurdles and the absence of emergency authorization pathways comparable to Operation Warp Speed.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$117,642End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent outbreaks of hantavirus, including Andes virus cases in 2026, have intensified research interest, yet all leading candidates remain in early preclinical stages with mRNA, DNA, and subunit platforms still undergoing animal testing and immunogenicity studies. Standard regulatory pathways for novel vaccines require sequential Phase 1–3 human trials plus manufacturing scale-up, timelines that typically span several years even under accelerated conditions, with no candidates currently positioned for 2026 approval or licensure outside limited existing options like South Korea’s Hantavax. Trader consensus at 93.5% “No” reflects these extended development hurdles and the absence of emergency authorization pathways comparable to Operation Warp Speed.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$117,642End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Recent outbreaks of hantavirus, including Andes virus cases in 2026, have intensified research interest, yet all leading candidates remain in early preclinical stages with mRNA, DNA, and subunit platforms still undergoing animal testing and immunogenicity studies. Standard regulatory pathways for novel vaccines require sequential Phase 1–3 human trials plus manufacturing scale-up, timelines that typically span several years even under accelerated conditions, with no candidates currently positioned for 2026 approval or licensure outside limited existing options like South Korea’s Hantavax. Trader consensus at 93.5% “No” reflects these extended development hurdles and the absence of emergency authorization pathways comparable to Operation Warp Speed.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions